Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01315210 · ClinicalTrials.gov registry record · Phase 2

D-Ribose for Fatigue in Subjects With Fibromyalgia

A Phase 2 study of Fibromyalgia, sponsored by RiboCor.

Completed
Registry status
Phase 2
Development phase
110
Enrollment target
9
Study locations

NCT01315210: Completed Phase 2 study of Fibromyalgia, sponsored by RiboCor.

NCT01315210 is a Phase 2 study of Fibromyalgia that has completed, run by RiboCor. The registered enrollment target is 110 participants, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (38% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01315210, a Phase 2 study of Fibromyalgia, has completed, sponsored by RiboCor.

COMPLETED
Registry status
Phase 2
Development phase
110 participants
Enrollment target
9
Study locations

Study Summary

To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a day (TID) over a 12-week period to subjects who are experiencing fatigue associated with a diagnosis of fibromyalgia.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo Powder
  • DRUG D-Ribose Powder

Study Locations (9)

Florida

  • Avail Clinical Research - DeLand
  • Renstar Medical Research - Ocala

Maryland

  • Columbia Medical Practice - Columbia
  • The Center for Rheumatology and Bone Research - Wheaton

North Carolina

  • Peters Medical Research - High Point
  • Wake Research Associates, LLC - Raleigh

California

  • Superior Research, LLC - Sacramento

Kentucky

  • University of Kentucky - Lexington

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2011-05
Est. Completion 2012-10
Phase Phase 2
RiboCor

1 total trials

What the finished NCT01315210 record still lists

NCT01315210 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (38% lower).

The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo Powder is the first listed.

NCT01315210 lists 9 locations in 6 states (Florida, Maryland, North Carolina).

Frequently Asked Questions

What is clinical trial NCT01315210 about?

NCT01315210 is a clinical study titled "D-Ribose for Fatigue in Subjects With Fibromyalgia". To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a d...

What is the current status of trial NCT01315210?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2011-05. Estimated completion is 2012-10.

What conditions does trial NCT01315210 study?

This clinical trial studies the following conditions: Fibromyalgia.

What interventions are being tested in trial NCT01315210?

The interventions under investigation include: Placebo Powder (DIETARY_SUPPLEMENT), D-Ribose Powder (DRUG).

Who is sponsoring clinical trial NCT01315210?

This trial is sponsored by RiboCor, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01315210 being conducted?

This trial has 9 study locations across California, Florida, Kentucky, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fibromyalgia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01315210's enrollment target sits among peer trials

110 29th of 76 higher than 48 of 76 other Fibromyalgia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01315210, the US trial registry maintained by the National Library of Medicine. NCT01315210 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.